Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14488570 | 0.85 | NR1H2 (0.42) | PEPDNR1H2NR1H3IMPDH2PTPN1 | |
| SCHEMBL18084469 | 0.85 | NR1H2 (0.42) | PEPDNR1H2NR1H3IMPDH2PTPN1 | |
| SCHEMBL13859052 | 0.74 | PEPD (0.49) | PEPDNR1H2NR1H3IMPDH2PTPN1 | |
| SCHEMBL27274306 | 0.74 | PEPD (0.49) | PEPDNR1H2NR1H3IMPDH2PTPN1 | |
| SCHEMBL12773345 | 0.74 | PEPD (0.49) | PEPDNR1H2NR1H3IMPDH2PTPN1 | |
| SCHEMBL8255174 | 0.73 | NR1H2 (0.42) | NR1H2NR1H3IMPDH2PTPN1SMN1; SMN2 | |
| SCHEMBL14488388 | 0.73 | HSD17B10 (0.46) | NR1H2NR1H3SMN1; SMN2HSD17B10KDM1A | |
| SCHEMBL16824583 | 0.73 | HSD17B10 (0.46) | NR1H2NR1H3SMN1; SMN2HSD17B10KDM1A | |
| SCHEMBL934024 | 0.73 | HSD17B10 (0.46) | NR1H2NR1H3SMN1; SMN2HSD17B10KDM1A | |
| SCHEMBL19389900 | 0.73 | HSD17B10 (0.40) | SMN1; SMN2HSD17B10GPR119KDM1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028519-A1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5] OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028519-A1 | (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5] OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION | SOST, BMP6, BMP1 | PEPD 2272/4885NR1H2 1150/4885NR1H3 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.